DaVita (DVA) is back in focus after recent analyst commentary highlighted higher consensus earnings estimates for the company and a P/E of 12.91 compared with 26.10 for its industry.

The analyst revisions and relatively lower P/E multiple come on top of a powerful run in the stock, with a 30-day share price return of 30.73% and year-to-date share price return of 73.36%. The 3-year total shareholder return of 110.56% points to momentum that has been building over several years rather than just in recent weeks.

If DaVita’s move has you thinking about where else the market is repricing healthcare risk and opportunity, it could be a good time to check out 34 healthcare AI stocks

With DaVita trading on a lower P/E than its industry after such a strong share price run, the key question now is whether the stock still offers value or if the market is already pricing in future growth.

Most Popular Narrative: 3% Overvalued

DaVita's most followed narrative sees fair value at $193.71 compared with the last close of $198.52, which frames the current debate around how much of the dialysis story is already reflected in the price.

The aging population and rising rates of diabetes and hypertension continue to fuel steady underlying demand for dialysis, and management reaffirmed their belief in a return to 2% annual treatment growth over time, suggesting upside to revenue as volumes recover from temporary disruptions. Ongoing investments in technology, AI, and data analytics are driving structural cost reductions through improved operational efficiency and enhanced clinical outcomes, which management expects to support margin improvement even in periods of flat or negative volume growth.

Want to see how recurring treatment volumes, margin rebuild and future earnings assumptions connect to that fair value line? The core narrative leans heavily on steady revenue expansion, improving profitability and a tighter share count that together shape its long term earnings profile.

Result: Fair Value of $193.71 (OVERVALUED)

However, investors still need to weigh risks such as reimbursement rates lagging cost inflation and potential volume pressure from GLP-1 treatments, which could challenge those earnings assumptions.

Another View on Valuation

While the fair value narrative points to DaVita as 3% overvalued at $193.71 versus a $198.52 share price, the SWS DCF model is more cautious, with a future cash flow value of $142.30. This frames the stock as overvalued using that method as well. Which set of assumptions feels more realistic to you?

Next Steps

Given the mix of optimism and caution throughout this article, it makes sense to act promptly, review the numbers yourself, and weigh both sides with 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If DaVita has sharpened your focus, do not stop here, fresh ideas across sectors can help you build a more resilient watchlist and broaden your opportunity set.

• Scan for potential value opportunities that pair quality fundamentals with attractive pricing by running the 49 high quality undervalued stocks.
• Target consistency with companies that prioritise robust finances and steady operations using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot overlooked opportunities early by reviewing the screener containing 21 high quality undiscovered gems before they gain wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.